Volume 13, Issue 1
Main Paper

A practical guide to Bayesian group sequential designs

Thomas Gsponer

Corresponding Author

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

Correspondence to: Heinz Schmidli, Novartis Pharma AG, PO Box, CH‐4002 Basel, Switzerland.

E‐mail: heinz.schmidli@novartis.com

Search for more papers by this author
Florian Gerber

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

Search for more papers by this author
Björn Bornkamp

Statistical Methodology, Novartis Pharma AG, Basel, Switzerland

Search for more papers by this author
David Ohlssen

Statistical Methodology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Search for more papers by this author
Marc Vandemeulebroecke

Integrated Information Sciences, Novartis Pharma AG, Basel, Switzerland

Search for more papers by this author
Heinz Schmidli

Statistical Methodology, Novartis Pharma AG, Basel, Switzerland

Search for more papers by this author
First published: 24 August 2013
Citations: 25
Supporting information may be found in the online version of this article.

Abstract

Bayesian approaches to the monitoring of group sequential designs have two main advantages compared with classical group sequential designs: first, they facilitate implementation of interim success and futility criteria that are tailored to the subsequent decision making, and second, they allow inclusion of prior information on the treatment difference and on the control group. A general class of Bayesian group sequential designs is presented, where multiple criteria based on the posterior distribution can be defined to reflect clinically meaningful decision criteria on whether to stop or continue the trial at the interim analyses. To evaluate the frequentist operating characteristics of these designs, both simulation methods and numerical integration methods are proposed, as implemented in the corresponding R package gsbDesign. Normal approximations are used to allow fast calculation of these characteristics for various endpoints. The practical implementation of the approach is illustrated with several clinical trial examples from different phases of drug development, with various endpoints, and informative priors. Copyright © 2013 John Wiley & Sons, Ltd.

Number of times cited according to CrossRef: 25

  • Comparison of Bayesian and frequentist group-sequential clinical trial designs, BMC Medical Research Methodology, 10.1186/s12874-019-0892-8, 20, 1, (2020).
  • Surgery for women with endometrioma prior to in vitro fertilisation: proposal for a feasible multicentre randomised clinical trial in the UK, Human Reproduction Open, 10.1093/hropen/hoaa012, 2020, 3, (2020).
  • The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design, Trials, 10.1186/s13063-020-04334-x, 21, 1, (2020).
  • The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design, BMJ, 10.1136/bmj.m115, (m115), (2020).
  • The P value line dance: when does the music stop? (Preprint), Journal of Medical Internet Research, 10.2196/21345, (2020).
  • Efficient adaptive designs for clinical trials of interventions for COVID-19, Statistics in Biopharmaceutical Research, 10.1080/19466315.2020.1790415, (1-26), (2020).
  • Beyond Randomized Clinical Trials: Use of External Controls, Clinical Pharmacology & Therapeutics, 10.1002/cpt.1723, 107, 4, (806-816), (2019).
  • Bayesian Reduced Rank Regression for Classification, Applications in Statistical Computing, 10.1007/978-3-030-25147-5_2, (19-30), (2019).
  • A Comparison Between a Meta-analytic Approach and Power Prior Approach to Using Historical Control Information in Clinical Trials With Binary Endpoints, Therapeutic Innovation & Regulatory Science, 10.1177/2168479019862531, (216847901986253), (2019).
  • Bayesian sample size re-estimation using power priors, Statistical Methods in Medical Research, 10.1177/0962280218772315, 28, 6, (1664-1675), (2018).
  • Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2018.1489400, 29, 1, (189-202), (2018).
  • Conditional estimation using prior information in 2‐stage group sequential designs assuming asymptotic normality when the trial terminated early, Pharmaceutical Statistics, 10.1002/pst.1859, 17, 5, (400-413), (2018).
  • Adaptive designs in clinical trials: why use them, and how to run and report them, BMC Medicine, 10.1186/s12916-018-1017-7, 16, 1, (2018).
  • Beyond p -values: A phase II dual-criterion design with statistical significance and clinical relevance , Clinical Trials, 10.1177/1740774518770661, 15, 5, (452-461), (2018).
  • Group sequential designs for negative binomial outcomes, Statistical Methods in Medical Research, 10.1177/0962280218773115, (096228021877311), (2018).
  • Sample size re‐estimation incorporating prior information on a nuisance parameter, Pharmaceutical Statistics, 10.1002/pst.1837, 17, 2, (126-143), (2017).
  • Bayesian randomized clinical trials: From fixed to adaptive design, Contemporary Clinical Trials, 10.1016/j.cct.2017.04.010, 59, (77-86), (2017).
  • Meta-analytic-predictive use of historical variance data for the design and analysis of clinical trials, Computational Statistics & Data Analysis, 10.1016/j.csda.2016.08.007, 113, (100-110), (2017).
  • Bayesian clinical trial designs, Journal of Trauma and Acute Care Surgery, 10.1097/TA.0000000000001638, 83, 4, (736-741), (2017).
  • Increasing efficiency of preclinical research by group sequential designs, PLOS Biology, 10.1371/journal.pbio.2001307, 15, 3, (e2001307), (2017).
  • Bayesian Phase II optimization for time-to-event data based on historical information, Statistical Methods in Medical Research, 10.1177/0962280217747310, (096228021774731), (2017).
  • Bayesian survival analysis in clinical trials: What methods are used in practice?, Clinical Trials: Journal of the Society for Clinical Trials, 10.1177/1740774516673362, 14, 1, (78-87), (2016).
  • Idle thoughts of a ‘well‐calibrated’ Bayesian in clinical drug development, Pharmaceutical Statistics, 10.1002/pst.1736, 15, 2, (96-108), (2016).
  • Near real‐time vaccine safety surveillance using electronic health records—a systematic review of the application of statistical methods , Pharmacoepidemiology and Drug Safety, 10.1002/pds.3966, 25, 3, (225-237), (2016).
  • Bayesian Design of Proof-of-Concept Trials, Therapeutic Innovation & Regulatory Science, 10.1177/2168479014533970, 49, 1, (155-162), (2014).

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.